Source comparison
Tesamorelin vs Egrifta: Practical Comparison
Active Compound Tesamorelin (44-amino-acid GHRH analog) Tesamorelin (identical sequence) Molecular structure is identical. No proprietary modification in Egrifta Regulatory Status FDA-approved prescription drug (2010) Research chemical (not FDA-approved for hu
This comparison does not assign a generated winner or score.
- Active Compound
- Tesamorelin (44-amino-acid GHRH analog)
- Tesamorelin (identical sequence)
- Molecular structure is identical. No proprietary modification in Egrifta
- Regulatory Status
- FDA-approved prescription drug (2010)
- Research chemical (not FDA-approved for human use)
- Egrifta undergoes batch-level FDA oversight; research peptides rely on supplier QC
- Approved Indication
- HIV-associated lipodystrophy (excess visceral adipose tissue)
- Investigational use only (in vitro, animal models, IRB-approved studies)
- Egrifta is the only FDA-cleared tesamorelin formulation for clinical prescription
- Typical Vial Size
- 1mg or 2mg lyophilized powder
- 2mg, 5mg, or 10mg lyophilized powder
- Research suppliers offer larger vial sizes for lab efficiency
- Purity Verification
- FDA-mandated CGMP with batch potency testing
- Third-party HPLC and mass spec (supplier-dependent)
- Both can achieve ≥98% purity. Egrifta has traceability; research peptides require vendor vetting
- Cost (per 2mg dose)
- $80–$120 (with insurance coverage often reducing out-of-pocket to $20–$40)
- $35–$65 (unregulated pricing, no insurance coverage)
- Research-grade is significantly cheaper but lacks prescription pathway